The net loss of PJSC Pharmaceutical Company Darnitsa (Kyiv) in January-June 2025 amounted to UAH 479.473 million, while in the same period of 2024, the company received UAH 6.528 million in net profit.
According to the company’s disclosure to the National Securities and Stock Market Commission, the net loss from sales in the first half of 2025 amounted to UAH 380.233 million, while in the same period of 2024, the profit from sales amounted to UAH 119.452 million.
As reported, Darnitsa’s net loss in January-March 2025 amounted to UAH 231.077 million, while in the same period of 2024, the company received UAH 19.484 million in net profit. Net sales revenue for the first quarter of 2025 decreased by 17.4% to almost UAH 1.018 billion.
In 2024, Darnitsa registered 10 drugs outside Ukraine and entered six new markets, including EU countries, Bosnia and Herzegovina, Israel, New Zealand, and Malaysia. In total, Darnitsa’s drugs are represented in more than 20 countries around the world.
At the end of 2024, exports accounted for 3.5% of the company’s sales. At the end of 2023, exports accounted for 4%. Exports were made to 17 countries.
Darnitsa has been present on the market for over 90 years, is one of the top 10 pharmaceutical manufacturers in Ukraine, and produces 180 brands of medicines in 15 different forms. The strategic areas of portfolio development are cardiology, neurology, and pain management.
According to the Unified State Register of Legal Entities and Individual Entrepreneurs, the ultimate beneficiary of the company is Gleb Zagoriy.
